Editing Azapirone (section)

==Medical uses==
Azapirones have shown benefit in general anxiety<ref>{{Cite journal|title = Azapirones for generalized anxiety disorder.|journal = Reviews|doi = 10.1002/14651858.CD006115|pmid = 16856115 |issue=3 |year=2006 |pages=CD006115 |vauthors=Chessick CA, Allen MH, Thase M | volume=2015 | pmc=8915394 |display-authors=etal}}</ref> and augmenting SSRIs in social anxiety<ref>{{Cite book|chapter = Pharmacological treatment of social anxiety disorder|date = Sep 20, 2013 |doi = 10.1159/000351960|pmid = 25225024 |volume=29 |pages=144–53 |vauthors=Masdrakis VG, Turic D, Baldwin DS |isbn = 978-3-318-02463-0|title = Anxiety Disorders|series = Modern Trends in Pharmacopsychiatry}}</ref> and depression.<ref>{{Cite journal|title = Serotonergic drugs for depression and beyond|date = May 1, 2013|last1 = Stahl |first1=SM |last2 =Lee-Zimmerman |first2=C |journal = Curr Drug Targets|pmid = 23531115 |volume=14 |issue=5 |pages=578–85 |doi=10.2174/1389450111314050007}}</ref> Evidence is not clear for [[panic disorder]]<ref>{{cite journal|last1=Imai|first1=H|last2=Tajika|first2=A|last3=Chen|first3=P|last4=Pompoli|first4=A|last5=Guaiana|first5=G|last6=Castellazzi|first6=M|last7=Bighelli|first7=I|last8=Girlanda|first8=F|last9=Barbui|first9=C|last10=Koesters|first10=M|last11=Cipriani|first11=A|last12=Furukawa|first12=TA|title=Azapirones versus placebo for panic disorder in adults|journal=The Cochrane Database of Systematic Reviews|date=Sep 30, 2014|volume=2014|issue=9|pages=CD010828|pmid=25268297|doi=10.1002/14651858.CD010828.pub2|pmc=10590499}}</ref> and [[functional gastrointestinal disorder]]s.<ref>{{Cite journal|title = Effects on gastrointestinal functions and symptoms of serotonergic psychoactive agents used in functional gastrointestinal diseases|date = Feb 2013|journal = J Gastroenterol|doi = 10.1007/s00535-012-0726-5|pmid = 23254779 |volume=48 |issue=2 |pages=177–81 |pmc=3698430 |vauthors=Grover M, Camilleri M}}</ref>

[[Tandospirone]] has also been used to augment antipsychotics in [[Japan]] as it improves [[Schizophrenia#Positive and negative|cognitive]] and [[Schizophrenia#Positive and negative|negative symptom]]s of [[schizophrenia]].<ref name="pmid11579010">{{cite journal |vauthors=Sumiyoshi T, Matsui M, Nohara S | title = Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment | journal = The American Journal of Psychiatry | volume = 158 | issue = 10 | pages = 1722–5 |date=October 2001 | pmid = 11579010 | doi = 10.1176/appi.ajp.158.10.1722|display-authors=etal}}</ref> [[Buspirone]] is being investigated for this purpose as well.<ref name="pmid17628435">{{cite journal |vauthors=Sumiyoshi T, Park S, Jayathilake K, Roy A, Ertugrul A, Meltzer HY | title = Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study | journal = Schizophrenia Research | volume = 95 | issue = 1–3 | pages = 158–68 |date=September 2007 | pmid = 17628435 | doi = 10.1016/j.schres.2007.06.008 | s2cid = 36027848 }}</ref><ref name="pmid19637398">{{cite journal |vauthors=Piskulić D, Olver JS, Maruff P, Norman TR | title = Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist | journal = Human Psychopharmacology | volume = 24 | issue = 6 | pages = 437–46 |date=August 2009 | pmid = 19637398 |  doi = 10.1002/hup.1046| s2cid = 21289248 | doi-access = free }}</ref>